Yang ZM - Search Results

1

Regulatory considerations for paediatric drug evaluation in China.

Geng Y, Li Q, Sun YZ, Zhang H, Jiang YL, Wang LQ, Wu YE, Zhao W, Yang ZM. Geng Y, et al. Among authors: yang zm. BMJ Paediatr Open. 2023 May;7(1):e001666. doi: 10.1136/bmjpo-2022-001666. BMJ Paediatr Open. 2023. PMID: 37130653 Free PMC article. Review.

2

The changing landscape of clinical trial and approval processes in China.

Zhou Q, Chen XY, Yang ZM, Wu YL. Zhou Q, et al. Among authors: yang zm. Nat Rev Clin Oncol. 2017 Sep;14(9):577-583. doi: 10.1038/nrclinonc.2017.10. Epub 2017 Feb 14. Nat Rev Clin Oncol. 2017. PMID: 28195238 Review.

3

Selection and measurement of control antidepressants in clinical tests for Chinese: A systematic review.

Liu H, Yang ZM, Geng Y, Yang H, Zhao DH, Xiao WD, Wang GH. Liu H, et al. Among authors: yang zm, yang h. Medicine (Baltimore). 2017 Oct;96(43):e8327. doi: 10.1097/MD.0000000000008327. Medicine (Baltimore). 2017. PMID: 29069004 Free PMC article. Review.

4

[Considerations on Clinical Development and Regulatory of the Oversea License-in  Anti-tumor Drugs].

Zhao X, Hao R, Tong X, Zou L, Tang L, Zhang H, Xia L, Yang Z. Zhao X, et al. Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):448-451. doi: 10.3779/j.issn.1009-3419.2022.101.27. Zhongguo Fei Ai Za Zhi. 2022. PMID: 35899440 Free PMC article. Chinese.

5

Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers.

Zou L, Qi Y, Jiang Y, Tang L, Du Y, Zhao B, Sun Y, Xiang M, Ma J, Yang Z. Zou L, et al. Cancer Commun (Lond). 2023 Feb;43(2):171-176. doi: 10.1002/cac2.12400. Epub 2023 Jan 22. Cancer Commun (Lond). 2023. PMID: 36683350 Free PMC article. No abstract available.

6

Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.

Li N, Huang HY, Wu DW, Yang ZM, Wang J, Wang JS, Wang SH, Fang H, Yu Y, Bai Y, Yan Z, Cao Y, Jiang M, Liu YF, Li KY, Xu BH, Sun Y, He J. Li N, et al. Among authors: yang zm. Lancet Oncol. 2019 Nov;20(11):e619-e626. doi: 10.1016/S1470-2045(19)30491-7. Lancet Oncol. 2019. PMID: 31674320

7

Anticancer drug R&D landscape in China.

Zhao S, Zhao H, Lv C, Gong J, Zhang J, Fang W, Li J, Hu X, Ba Y, Xu B, Zhang Y, Fan Y, Li K, Chen X, Yang Z, Shen L, Zhang L. Zhao S, et al. J Hematol Oncol. 2020 May 13;13(1):51. doi: 10.1186/s13045-020-00877-3. J Hematol Oncol. 2020. PMID: 32404176 Free PMC article. No abstract available.

8

[Consideration on the Research and Development of New Drugs for Rare Tumors].

Tang L, Song Y, Yang Z. Tang L, et al. Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):443-447. doi: 10.3779/j.issn.1009-3419.2022.101.26. Zhongguo Fei Ai Za Zhi. 2022. PMID: 35899439 Free PMC article. Chinese.

9

Clinical review considerations of class I PI3K inhibitors in hematolymphatic malignancies by Center for Drug Evaluation.

Zou L, Qi Y, Tang L, Du Y, Xiang M, Chen X, Ma J, Yang Z. Zou L, et al. Chin J Cancer Res. 2022 Aug 30;34(4):415-421. doi: 10.21147/j.issn.1000-9604.2022.04.09. Chin J Cancer Res. 2022. PMID: 36199534 Free PMC article.

10

Accelerating the integration of China into the global development of innovative anticancer drugs.

Huang H, Wu D, Miao H, Tang Y, Liu C, Fang H, Meng X, Wang S, Zhu Q, Wang X, Du J, Yang Z, Li N, Xu B, He J. Huang H, et al. Lancet Oncol. 2022 Nov;23(11):e515-e520. doi: 10.1016/S1470-2045(22)00483-1. Lancet Oncol. 2022. PMID: 36328025 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

582 results

Search Page